Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
STRO
vs
S&P 500
STRO
S&P 500
Over the past 12 months, STRO has underperformed S&P 500, delivering a return of -17% compared to S&P 500's +11% growth.
Stocks Performance
STRO vs S&P 500
Performance Gap
STRO vs S&P 500
Performance By Year
STRO vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Sutro Biopharma Inc
Glance View
Sutro Biopharma is a biotechnology company that designs cancer drugs, especially antibody-drug conjugates and other targeted biologic medicines. Its main job is to build drug candidates that can carry a cancer-killing payload directly to tumor cells while trying to spare healthy tissue. The company sells the drugs themselves only if they are approved in the future, so today it is mainly focused on research and development. Its core technology is a cell-free protein manufacturing platform that helps it make and test complex protein-based medicines that can be harder to produce with standard methods. Sutro also works with pharmaceutical partners through collaborations, which can bring in upfront payments, research funding, milestone payments, and royalties if partnered programs succeed. That means part of its business is as a drug developer and part is as a technology partner. Sutro’s main customers are not everyday consumers but cancer patients, hospitals, and drugmakers. In the near term, it depends on research partnerships and financing to support development; in the long run, it would make money from approved medicines and from licensing or sharing rights to its drug candidates. Its role is different because it sits earlier in the drug chain than most biopharma companies: it invents and engineers complex targeted therapies rather than just marketing finished drugs.